– USA, CA – Ambys Medicines, a cell and gene therapy company focused on advancing novel treatments to restore and regenerate liver function, today announced the appointment of Jennifer Cook to its Board of Directors.
“We are thrilled to welcome Jennifer to our board,” said Interim CEO and Executive Chairman, Dr. Jeffrey Tong. “Ambys is pursuing novel cell and gene therapy approaches to bring new therapeutic options to patients with advanced liver diseases. As we embark on this ambitious goal, we are fortunate to be able to draw on Jennifer’s deep insights and experience in leading organizations, developing products, and commercializing new medicines. The company and the entire board look forward to partnering with Jennifer.”
About Jennifer Cook
A highly respected biotechnology and pharmaceutical industry executive, Ms. Cook’s experience includes senior leadership roles globally and in the U.S. during her 25-year tenure at Roche Pharmaceuticals and Genentech, and also serving most recently as CEO at GRAIL, a healthcare company focused on the early detection of cancer. Ms. Cook is currently focused on providing advisory support to senior executives in the healthcare field.
Before serving as GRAIL’s CEO, Ms. Cook held several leadership positions with Roche/Genentech, including leading Roche Pharmaceuticals’ European commercial business, Global Clinical Operations, the U.S., and Global Product Portfolio Management, a U.S. Immunology & Ophthalmology Business Unit, and Market Development. She was honored as the Woman of the Year by the Healthcare Businesswomen’s Association in 2016 and was named one of the Most Influential Women in Business by The San Francisco Business Times in 2012.
“Advanced liver disease as a therapeutic area, unfortunately, hasn’t experienced the same pace of innovation that we’ve seen in other areas of drug development. Ambys is pursuing novel cell and gene therapies that I believe hold the potential to redirect that trajectory, shifting advanced liver disease to the forefront of scientific innovation,” said Ms. Cook. “I am truly excited to work hand in hand with Jeff, the Ambys team and my fellow Ambys board members as the company continues to progress its transformative medicines.”
Ms. Cook holds a BA in Human Biology and an MS in Biology from Stanford University, as well as an MBA from the Haas School of Business at the University of California, Berkeley. Ms. Cook also serves on the Boards of Directors of Denali Therapeutics and BridgeBio Pharma.
About Ambys Medicines
Ambys Medicines is a cell and gene therapy company focused on discovering and developing regenerative and restorative therapies for patients with advanced liver disease. Ambys is pioneering the application of cell and gene therapy to meet the urgent need for novel treatments for those suffering from severe acute and chronic liver diseases. Ambys was launched in 2018 by Third Rock Ventures and Takeda Pharmaceuticals and is headquartered in South San Francisco, California.
For more information: https://www.ambys.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
